FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| | | | | |
|------------|--------|------|------|--|
| ashington, | D.C. 2 | 0549 | | |

| Washington, D.C. 20549 | OMB APPROVA | | | |
|----------------------------------------------|-------------|-----|--|--|
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | OMB Number: | 323 | | |

| OMB Number: | 3235-028 |
|----------------------|----------|
| Estimated average bu | ırden |
| hours per response: | 0. |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Nagend (Last) | dran Suku | rst) (| (Middle) | | Solid Biosciences Inc. [SLDB] 3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023 | | | | | | | | ck all appli Directo | icable) or (give title | ıg Per | son(s) to Is 10% Ov Other (s below) | vner | | |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------|----------|---------------------------------------|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------|---------------------|-----------------|---------------------------------------------------|-----------------|----------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------|------|---|--|
| C/O SOLID BIOSCIENCES INC. 500 RUTHERFORD AVENUE (Street) | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Inc Line) | X Form filed by One Reporting Person Form filed by More than One Reporting | | | | | |
| CHARLESTOWN MA 02129 | | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | | |
| (City) (State) (Zip) | | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) | | | | te | Execution Date, | | | Code (Instr. 5) | | | 4 and Securiti Benefic | | ies Form ially (D) of Following (I) (I | | n: Direct r Indirect istr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | Code | v | Amount | nt (A) or Prid | | rice | Transac | saction(s) r. 3 and 4) | | | (111311. 4) | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | rivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any | | Co | ansaction of ode (Instr. Derivative | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | [5 (| . Price of Perivative Security Instr. 5) | | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | Co | ode | v | (A) | (D) | Date Exercisable | Ex Da | piration te | Title | Amo or Num of Shar | ber | | | | | |
| Director Stock Option (Right to Buy) | \$6.37 | 06/06/2023 | | | A | | 9,650 | | (1) | 06. | /06/2033 | Common Stock | 9,6 | 50 | \$0.00 | 9,650 | | D | |

Explanation of Responses:

1. This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Remarks:

/s/ David Tyronne Howton as 06/08/2023 attorney-in-fact for Sukumar **Nagendran**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.